STOCK TITAN
  1. Home
  2. Sec-filings
  3. ROIV
  4. [Form 4] Roivant Sciences Ltd. Insider Trading Activity

Roivant Sciences president sells 200,000 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Roivant Sciences Ltd. (ROIV) reported that officer Eric Venker, President & Immunovant CEO, exercised stock options for 200,000 Common Shares at an exercise price of $3.85 per share and on the same date sold an aggregate of 200,000 Common Shares in multiple transactions at weighted average prices of $35.63 and $36.44 per share, under a Rule 10b5-1 trading plan adopted on March 28, 2025. Following the option exercise, Venker reported 3,844,834 stock options remaining directly held.

Positive

  • None.

Negative

  • None.
Insider Venker Eric
Role President & Immunovant CEO
Sold 200,000 shs ($7.15M)
Approx. gross sale proceeds $7.15M
Approx. exercise cost $770K
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F3 200,000 $0.00 $0.00
Exercise Common Shares 200,000 $3.85 $770K
Sale Common Shares F1 166,182 $35.63 $5.92M
Sale Common Shares F2 33,818 $36.44 $1.23M
Holdings After Transaction: Stock Option (Right to Buy) — 3,844,834 shares (Direct); Common Shares — 1,599,154 shares (Direct)
Footnotes (3)
  1. F1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.17 to $36.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.
  2. F2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.17 to $36.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.
  3. F3. Reflects an award of stock options to purchase Common Shares that is fully vested.
Options Exercised 200,000 shares Stock options for Common Shares exercised on 2026-08-28 at $3.85 per share
Exercise Price $3.85 per share Conversion or exercise price of stock options exercised for 200,000 shares
Shares Sold (Tranche 1) 166,182 shares at $35.63 per share Weighted average sale price; trades ranged from $35.17 to $36.16 on 2026-08-28
Shares Sold (Tranche 2) 33,818 shares at $36.44 per share Weighted average sale price; trades ranged from $36.17 to $36.80 on 2026-08-28
Net Shares Sold 200,000 shares transactionSummary netBuySellShares showing net-sell direction
Options Held After Exercise 3,844,834 options Total stock options following derivative transaction reported as directly owned
Rule 10b5-1 Plan Adoption Date March 28, 2025 Footnotes state sales were effected pursuant to a Rule 10b5-1 trading plan adopted on this date
Option Expiration Date April 19, 2032 Expiration date of the stock option series from which 200,000 options were exercised
Rule 10b5-1 trading plan regulatory
"These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock options financial
"Reflects an award of stock options to purchase Common Shares that is fully vested."
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
Common Shares financial
"These shares were sold in multiple transactions at prices ranging..."
Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

FAQ

What transactions did Eric Venker report in the latest Form 4 for ROIV?
Eric Venker exercised 200,000 stock options at $3.85 per share and sold 200,000 Common Shares on August 28, 2026 in multiple transactions at weighted average prices of $35.63 and $36.44 per share.

How many Roivant (ROIV) shares did Eric Venker sell and at what prices?
He sold a total of 200,000 Common Shares: 166,182 shares at a weighted average price of $35.63 (range $35.17–$36.16) and 33,818 shares at a weighted average price of $36.44 (range $36.17–$36.80).

What options did Eric Venker exercise in the Form 4 for ROIV?
He exercised fully vested stock options for 200,000 Common Shares with an exercise price of $3.85 per share, originally expiring on April 19, 2032, resulting in 3,844,834 stock options reported as held directly after the transaction.

Were Eric Venker’s ROIV share sales under a Rule 10b5-1 trading plan?
Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025, and the Rule 10b5-1 checkbox is affirmed for the filing.

Did Eric Venker buy or sell net shares of Roivant (ROIV) stock in this Form 4?
Net, he reported a sale of 200,000 shares. The summary shows 200,000 shares acquired through option exercise and 200,000 shares sold, with the transactionSummary indicating net-sell of 200,000 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Venker Eric
(Last)(First)(Middle)
C/O ROIVANT SCIENCES LTD.
7TH FLOOR, 50 BROADWAY
(Street)
LONDONSW1H 0DB
(City)(State)(Zip)
UNITED KINGDOM
(Country)		2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
President & Immunovant CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/28/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Shares08/28/2026M200,000A$3.851,799,154D
Common Shares08/28/2026S166,182D$35.63(1)1,632,972D
Common Shares08/28/2026S33,818D$36.44(2)1,599,154D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$3.8508/28/2026M200,000 (3)04/19/2032Common Stock200,000$03,844,834D
Explanation of Responses:
1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.17 to $36.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.
2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.17 to $36.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.
3. Reflects an award of stock options to purchase Common Shares that is fully vested.
By: /s/ Sam Kaplan, as Attorney-in-Fact for Eric Venker09/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR